E2027

DRUG5 trials

Sponsors

Eisai Inc., Eisai Co., Ltd.

Conditions

Dementias With Lewy BodiesHealthy ParticipantsHealthy SubjectsLewy Body DiseaseParkinson Disease

Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

CompletedNCT02415790

Eisai Inc.Healthy Participants

Start: 2015-07-31End: 2016-07-31Updated: 2017-03-08

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

CompletedNCT02873156

Eisai Inc.Healthy Subjects

Start: 2016-08-10End: 2017-11-29Updated: 2018-09-07

Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

CompletedNCT02947711

Eisai Co., Ltd.Healthy Subjects

Start: 2016-10-31End: 2017-01-31Updated: 2017-03-07

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

CompletedNCT04023877

Eisai Inc.Dementias With Lewy Bodies

Start: 2019-07-18End: 2019-10-11Updated: 2019-12-03

Phase 2

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

CompletedNCT04764669

Eisai Inc.Lewy Body Disease, Parkinson Disease

Start: 2021-02-25End: 2022-01-27Updated: 2022-09-26